Moon Lake Immunotherapeutics MLTX
Institutional shares held
56 Million
379K
calls
402K
puts
Total value of holdings
$2.29B
$15.5M
calls
$16.4M
puts
Market Cap
$1.47B
36,925,600
Shares Out.
Institutional ownership
151.59%
# of Institutions
135
We take great care to ensure that the data presented and summarized in this overview for MoonLake Immunotherapeutics is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MLTX
View all-
Bvf Inc San Francisco, CA21.8MShares$865 Million32.73% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$338 Million24.56% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.58MShares$103 Million1.56% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.31MShares$91.8 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.28MShares$90.8 Million0.23% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.14MShares$84.9 Million0.01% of portfolio
-
Holocene Advisors, LP New York, NY1.45MShares$57.8 Million0.28% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA1.1MShares$43.7 Million0.13% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.1MShares$43.5 Million0.03% of portfolio
-
Alliancebernstein L.P. New York, NY956KShares$38 Million0.02% of portfolio
Latest Institutional Activity in MLTX
Top Purchases
Top Sells
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Insider Transactions at MLTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 29
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,740
-0.16%
|
$260,700
$55.89 P/Share
|
|
Feb 28
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
56,065
-1.84%
|
$3,083,575
$55.0 P/Share
|
|
Feb 28
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
28,090
-40.09%
|
$1,544,950
$55.0 P/Share
|
|
Feb 28
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
31,910
-1.08%
|
$1,755,050
$55.0 P/Share
|
|
Feb 27
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
62,810
-2.02%
|
$3,454,550
$55.0 P/Share
|
|
Feb 27
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
29,431
-29.58%
|
$1,618,705
$55.0 P/Share
|
|
Feb 27
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
29,491
-0.99%
|
$1,622,005
$55.0 P/Share
|
|
Feb 21
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,125
-0.04%
|
$61,875
$55.27 P/Share
|
|
Feb 21
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
569
-0.57%
|
$31,295
$55.3 P/Share
|
|
Feb 21
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
509
-0.02%
|
$27,995
$55.31 P/Share
|
|
Feb 20
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.09%
|
$570,000
$57.43 P/Share
|
|
Feb 20
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-0.33%
|
$570,000
$57.45 P/Share
|
|
Feb 20
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.64%
|
$1,140,000
$57.44 P/Share
|
|
Feb 16
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.64%
|
$1,200,000
$60.15 P/Share
|
|
Feb 16
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.33%
|
$600,000
$60.15 P/Share
|
|
Feb 16
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-0.33%
|
$600,000
$60.15 P/Share
|
|
Feb 15
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.63%
|
$1,200,000
$60.18 P/Share
|
|
Feb 15
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-7.69%
|
$600,000
$60.16 P/Share
|
|
Feb 15
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-0.33%
|
$600,000
$60.17 P/Share
|
|
Feb 14
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-7.14%
|
$620,000
$62.43 P/Share
|
Last 12 Months Summary
Buy / Acquisition
7.75M
Shares
From
5
Insiders
| Open market or private purchase | 1.6M shares |
|---|---|
| Conversion of derivative security | 6.14M shares |
Sell / Disposition
6.63M
Shares
From
7
Insiders
| Sale (or disposition) back to the issuer | 6.14M shares |
|---|---|
| Open market or private sale | 485K shares |